Medtech

How will COVID-19 vaccine rollout differ by country?

COVID-19 vaccination represents a critical component in the recovery of medtech markets for healthcare capacity, patient mobility and the full restoration of global manufacturing operations and supply chains. To understand the effect of various vaccination campaigns, we need to understand the rollout by region and country. Clarivate experts developed a vaccination forecast model to illustrate […]

Impact of COVID-19 vaccine rollout on medtech recovery

The COVID-19 pandemic impacted the fundamental operations of all healthcare stakeholders. The ability to predict the outcomes of the pandemic and the speed of recovery for medtech markets has been challenged by the lack of historical data. This article is an executive summary of a new report from Clarivate assessing how COVID-19 vaccine rollouts will […]

Patient advocates speak out on partnering with life science companies

What does patient centricity mean from a patient’s point of view, and what kind of support do patient advocates need from life science companies? Three prominent patient advocates shared their perspectives. In 2010, Nick Sireau, a London-based father of two boys with the rare progressive genetic disease alkaptonuria (or AKU, also known as “Black bone […]

DRG becomes Clarivate

One year ago, we welcomed Decision Resources Group (DRG) to the Clarivate portfolio of brands. Today we mark the next step in this journey as the DRG brand now becomes one with the Clarivate brand. Starting today, you will begin to see the DRG brand less and less as we migrate communications and, look and […]

CMS unveils new alternative payment models targeting rural health and therapy areas

CMS continues to evolve its alternative payment model strategy to include downside risk, where providers assume financial risk for quality and cost of care.  Approximately 36 percent of U.S. healthcare payments were tied to alternative payment models in 2018 per the Health Care Payment Learning & Action Network. CMS announced three shared-risk APMs earlier this […]

What drives the therapy selection test market?

Clarivate medtech expert Sophia Quraishi reviews key factors driving increased demand for premium-priced therapy selection tests.   Therapy selection tests are a form of liquid biopsy, which involve sequencing substrates isolated from bodily fluids, such as blood, saliva or urine. This approach is less invasive, can be used more often and is more cost effective […]

Six U.S. healthcare policy questions hanging in the balance

Insights provided in this article were developed using data on and analysis of the impact of U.S. policy on healthcare and the pharmaceutical industry by analysts at DRG, part of Clarivate. DRG U.S. Managed Markets Insights provides robust qualitative insights on national, state and MSA level market access dynamics.   Ten years after the passage […]

Role of advanced IDNs grows as COVID-19 shifts market dynamics

The COVID-19 pandemic is fundamentally changing healthcare delivery in the United States, from the acceptance of virtual physician visits to payment reform, and from the consolidation of integrated delivery networks to the very survival of independent physician practices. The resultant healthcare environment will be one that is more integrated into daily life with provider reimbursement […]

Physician practice ownership set for radical change as COVID-19 strains finances

The COVID-19 pandemic is fundamentally changing healthcare delivery in the United States, from the acceptance of virtual physician visits to payment reform, and from the consolidation of integrated delivery networks to the very survival of independent physician practices. Clarivate market access expert Heather Johnson discusses how physician practice ownership is expected to evolve due to the pandemic. […]